Avicena's Huntington's Disease Drug Candidate Selected as One of 100 Great Investigational Drugs of 2007 by R&D Directions

Avicena's Huntington's Disease Drug Candidate Selected as One of 100 Great Investigational Drugs of 2007 by R&D Directions: "Avicena Group, Inc. (OTC Bulletin Board: AVGOE), a biotechnology company focused on commercializing its proprietary cellular energy modulation technology, announced today that the pharmaceutical magazine R&D Directions selected Avicena's lead Huntington's disease drug candidate, HD-02, as one of the '100 Great Investigational Drugs of 2007' in the March issue."